SFM
PDSB icon

Signet Financial Management’s PDS Biotechnology PDSB Stock Holding History

Signet Financial Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-155
Closed -$4K – 1071
2018
Q1 		$4K Buy
+155
New +$41.7K ﹤0.01% 696

Other funds holding PDSB

SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GTC
Ghost Tree Capital New York $331M AUM 70.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Signet Financial Management's PDSB Position: Q2 2018 in Review

Signet Financial Management sold out of PDS Biotechnology (PDSB) in Q2 2018, closing a stake of 155 shares — an estimated $4K sold.

Signet Financial Management first reported a position in PDSB in Q1 2018 and held it in 1 quarter. The position peaked at $4K in Q1 2018. 43 funds tracked by Wall St. Rank hold PDSB as of Q2 2018.

  • Signet Financial Management reported no remaining PDS Biotechnology position as of Q2 2018 after selling out during the quarter.
  • Signet Financial Management sold 155 PDS Biotechnology shares in Q2 2018, an estimated $4K.
  • Signet Financial Management first reported a position in PDS Biotechnology in Q1 2018 and held it in 1 quarter.
  • Signet Financial Management's PDS Biotechnology position peaked at $4K in Q1 2018.
  • 43 funds tracked by Wall St. Rank held PDS Biotechnology as of Q2 2018.

Based on Signet Financial Management's 13F filing for Q2 2018, filed 10 Aug 2018.